Virtuoso (VOSO) Shareholders Approve Wejo Deal
by Marlena Haddad on 2021-11-17 at 7:47am

Virtuoso Acquisition Corp. (NASDAQ:VOSO) announced this morning that it has secured shareholder approval of its combination with vehicle data tracker Wejo at a shareholder meeting held yesterday.

The press release did not divulge redemption figures, but Virtuoso has taken steps to shore up its cash position ahead of the vote. It added $25 million in additional funding to its $100 million PIPE in June and last week brought in an additional investor for $3.5 million more.

At the same time, it announced it had arranged a forward purchase agreement (FPA) of up to $75 million with an affiliate of Apollo Global Management. Totaling $203.5 million, these PIPE and FPA additions more than clear the transaction’s $175 million minimum cash condition regardless of redemptions.

The deal is now expected to close on November 18 with the combined company’s shares and warrants set to begin trading on the Nasdaq the following day under the new ticker symbols, “WEJO” and “WEJOW,” respectively.

Virtuoso initially inked the $800 million deal with Wejo on May 28. Manchester, UK based Wejo enables smarter mobility by organizing data points from roughly 11.8 million vehicles and more than 58 billion journeys globally, across multiple brands, makes and models, and then standardizing and enhancing those streams of data on a vast scale.

The transaction included participation by strategic PIPE investors Microsoft (NASDAQ:MSFT), Palantir Technologies (NYSE:PLTR), and General Motors (NYSE:GM).


ADVISORS

  • Citigroup Global Markets Inc. is serving as exclusive financial advisor to Wejo.
  • Weil, Gotshal & Manges LLP is serving as legal counsel.
  • Moelis & Company LLC is serving as exclusive financial advisor to Virtuoso.
  • Arnold & Porter Kaye Scholer LLP is serving as legal counsel.
  • Moelis & Company LLC is acting as lead placement agent on the PIPE.
  • Cohen & Company Capital Markets (a division of J.V.B. Financial Group, LLC) and The Growth Stage also acted as placement agents on the PIPE.
  • BTIG, LLC and Moelis & Company LLC acted as joint bookrunners on Virtuoso’s $230mm IPO in January 2021 and are acting as joint capital markets advisors to Virtuoso.
Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved